Pictured above with her committee, Dr. Jacqueline Johnson successfully defended her dissertation on February 20, 2012. From left to right: Committee members Doug Cress and Eric Haura; Major Professor Srikumar Chellappan; Jacqueline Johnson; External Chair Philip Hinds, Deputy Director, Tufts Medical Center Cancer Center and Committee member Said Sebti. Jacqueline interviewed with a number of prestigious institutes before deciding to join the lab of Dr. Rene Bernards, Netherlands Cancer Institute, Amsterdam.
Recently, Dr. Johnson left her postdoctoral position to form a medical consulting company, JLJ Consultancy B.V. Dr. Johnson provides three categories of service to her clients: management consulting, medical communications and career coaching for PhDs wanting to transition from academia to industry.
Dr. Johnson's publication record while in the Program:
Johnson JL, Pillai S, Chellappan SP. Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int. 2012;2012:940405. doi: 10.1155/2012/940405. Epub 2012 Aug 15. PMID: 22928112
Singh S, Johnson J, Chellappan S. Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim Biophys Acta. 2010 Jul 15.
Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of Matrix Metalloproteinase Genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 2011 Nov 15.
Dr. Johnson's publication record since leaving the Program:
Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LF, Bernards R. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016 Feb 29. doi: 10.1038/onc.2016.32. Review PMID: 26923330